Source: Virtual Congress 2021 – Respiratory failure in COVID19 and beyond



Rating:

Share or cite this content

Citations should be made in the following way:
T. Pertseva (Dnipro, Ukraine), L. Konopkina (Dnipro, Ukraine), O. Myronenko (Dnipro, Ukraine), O. Shchudro (Dnipro, Ukraine). The dynamics of dyspnea in patients (pts) with pneumonia on the background of SARS-CoV2 infection. 3315

Member's Comments

No comment yet.

Related content which might interest you: The assessment of the metabolic dysfunction in patients (pts) after COVID-19 pneumonia Source: Virtual Congress 2021 – Pulmonary rehabilitation in the COVID-19 era Year: 2021 Definition of severity and the reasons for hospitalization (RH) in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 641s Year: 2005 How can I differentiate community-acquired pneumonia (CAP)+COPD patients from acute exacerbation of COPD (AECOPD) patients? Source: International Congress 2015 – Differentiating COPD exacerbations from pneumonia in COPD patients Year: 2015 Detection of liver function in patients with severe community-acquired pneumonia (CAP) Source: Eur Respir J 2002; 20: Suppl. 38, 15s Year: 2002 The estimation of respiratory muscles (RM) status by echodensitometry in male patients with acute exacerbation of COPD (AECOPD) Source: Annual Congress 2010 - Interaction between respiratory and peripheral muscles Year: 2010 The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP) Source: International Congress 2014 – Clinical presentations Year: 2014 An unbalanced inflammatory response on admission impacts clinical stability in hospitalized patients with community-acquired pneumonia (CAP) Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 Mental disorders in patients (pts) with COVID-19 pneumonia:comparison with COPD exacerbation Source: Virtual Congress 2021 – Long COVID - 19 Year: 2021 Enhanced neutrophil response in patients with chronic bronchitis and community-acquired pneumonia (CAP) Source: Eur Respir J 2002; 20: Suppl. 38, 418s Year: 2002 Acute phase proteins (APP) and serum iron in patients (pts) with simple community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 805s Year: 2006 Lower respiratory tract infection (LRTI): are there differences of microbial spectrum in stable phase (SP) of COPD and during acute exacerbation (AE)? Source: Annual Congress 2009 - COPD: exacerbation and clinical problems Year: 2009 Evaluation of Behcet‘s disease patients who admitted with pulmonary symptoms (analysis of 14 cases) Source: Annual Congress 2007 - Miscellaneous interstitial lung diseases related to systemic and other diseases Year: 2007 The incidence of Q fever in hospitalized patients with community acquired pneumonia Source: Annual Congress 2008 - Diagnostic tests in lower respiratory tract infections Year: 2008 Differential therapy of acute respiratory failure (ARF) in chronic obstructive pulmonary disease (COPD) patients with predominance of emphysema (PE) and predominance of bronchitis (PB) Source: Eur Respir J 2006; 28: Suppl. 50, 395s Year: 2006 Influence of thiotriazolin on phlegm cytogram of patients with community acquired pneumonia (CAP) Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases Year: 2008 Does the condition of chronic obstructive pumonary disease (COPD) have a prognostic benefit in patients with community-acquired pneumonia (CAP)? Source: Eur Respir J 2003; 22: Suppl. 45, 338s Year: 2003 An outbreak of pneumococcal-chlamydial pneumonia and acute respiratory disease (ARD) among trainees Source: Eur Respir J 2001; 18: Suppl. 33, 464s Year: 2001 Incidence of severe sepsis as a cause of clinical failure in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2007; 30: Suppl. 51, 42s Year: 2007 Is it connection between systemic inflammation and risk of thrombotic disorders (by Padua scale) in hospitalized patients with community-acquired pneumonia (CAP)? Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection Year: 2018 A delay in reaching time to clinical stability (tcs) for hospitalized patients with community-acquired pneumonia (CAP) is associated with failure within 30 days after hospital discharge Source: Annual Congress 2009 - Ventilator-associated pneumonia, severe community-acquired pneumonia and healthcare associated pneumonia Year: 2009